Tirzepatide Research Dosing

About Tirzepatide

Tirzepatide is a dual agonist for GLP-1 and GIP receptors, originally developed for Type-2 diabetes but now widely used in obesity research. It reduces appetite, improves metabolic rate, and assists in significant weight reduction.

Mechanism of Action

• GLP-1: Suppresses appetite and increases post-meal fullness.
• GIP: Enhances insulin secretion and energy balance.

Benefits

• Average weight loss: 24.7% after 72 weeks
• Reduces appetite and cravings
• Enhances satiety and energy balance
• Improves insulin sensitivity
• Supports fat oxidation

Possible Side Effects

Often mild and temporary (affect ~25% in trials):

• Nausea, vomiting, diarrhea, constipation
• Injection site reactions
• Fatigue, decreased appetite
• Dyspepsia, abdominal pain
• Burping (may be sulfur-like)
• Hair loss

Rare Risks: Thyroid tumors, pancreatitis, gastroparesis, hypoglycemia, gallbladder disease, kidney issues, pulmonary aspiration under anesthesia.

Contraindications

• Pregnant or breastfeeding
• History of Medullary Thyroid Carcinoma or MEN 2
• Type-1 diabetes or severe GI disease
• Allergy to Tirzepatide

Dosing Instructions

Mix with BAC water. Dose once weekly on the same day. Stay on each dose for minimum 4 weeks before escalating.

10mg Vial

• Reconstitution: 0.5mL (50 units)

30mg Vial

• Reconstitution: 1.5mL (150 units)

60mg Vial

• Reconstitution: 3mL (300 units)

Stacking Suggestions

• AOD-9604 – fat breakdown & weight loss
• Tesamorelin – visceral fat reduction
• Semax / Selank – mood & cognitive support
• NAD+ / MOTS-C – energy & metabolism
• BPC-157 – gut healing support
• CJC-1295 / Ipamorelin – muscle maintenance

Disclaimer

All information is strictly for laboratory and educational research. Not for human or veterinary use unless prescribed by a licensed medical professional.